Skip to main content

Table 3 Adjusted means (95% CI) of diagnosis-specific primary effectiveness measures, diagnosis-specific group differences and minimal clinical important differences, 6 months of follow-up

From: Effectiveness and cost-effectiveness of treatment with additional enrollment to a homeopathic integrated care contract in Germany

  HOM group CON group  
Diagnosis N Adj. mean (95% CI) N Adj. mean (95% CI) Group Δ* p-value Minimal clinical important difference reached?
Migraine/headache
Days with headache (last 4 weeks)
400 3.7 (2.2–5.2) 266 4.6 (2.9–6.3) −0.9 0.042 No
Allergic rhinitis
RQLQ(S) score
283 1.6 (1–2.2) 167 1.8 (1.2–2.5) −0.2 0.209 No
Asthma
AQLQ(S) score
111 5.8 (5.4–6.3) 66 5.4 (4.9–5.9) 0.4 0.014 No
Atopic dermatitis
DLQI score
206 6.8 (4.5–9.1) 97 8.2 (5.5–10.9) − 1.4 0.086 No
Depression
BDI-II score
423 14.1 (11.9–16.3) 334 19.7 (17.2–22.2) −5,6 < 0.001 Yes
  1. *HOM group minus CON group, adjusted for age, sex, education, residential state, complementary medicine affiliation, per protocol initial anamnesis, baseline value of diagnosis specific scores, Minimal clinical important differences refer to the diagnoses specific primary effectiveness outcomes (see Table 1), judgement for migraine/headache depends on expert opinion